Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T19:56:36.524Z.
Calculation as of: 2026-10-06T19:56:36.524Z.
Quote observation: 2026-10-06T19:53:43.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 16b0ce149acf027305ec47ed69e441f7c4eae43bc3095c7aeda967d53938ba16
PEG RATIO
N/A
Enlivex Therapeutics Ltd.
Market Cap
$5.85M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Enlivex Therapeutics Ltd. (ENLV) | $5.85M | N/A |
| Lucyd, Inc (LUCY)vs › | $5.86M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.90M | N/A |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.79M | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.76M | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.68M | N/A |
| Scienture Holdings, Inc. (SCNX)vs › | $6.01M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.56M | N/A |
| Femasys Inc. (FEMY)vs › | $6.25M | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.33M | N/A |
PEG Ratio
N/A
P/E Ratio
0.0
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
